실시간

FierceBiotechIn next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach CellDecoding the spatiotemporal development of human meninges CellFronto-insular circuit mechanisms of accelerated intermittent theta burst stimulation CellPhysiological brain clearance architecture revealed by neuronal protein tracing FierceBiotechASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’Endpoints NewsCan AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more IlluminaIllumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360 BioPharma DiveAt ASCO, Merck makes case for a ‘cornerstone’ cancer drug BioPharma DiveBristol Myers unveils data for one of its next-gen blood cancer drugs Clinical OMICsTeclistamab Outperforms Standard Therapy in Relapsed Multiple Myeloma Clinical OMICsAI Chatbots Do Not Consistently Deliver Accurate Health Responses FierceBiotechLegend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform

Labiotech 2026년 5월 29일

Can WEE1 inhibitors finally make replication stress druggable?

Find out about how biotech companies are trying to address the limits the first generation of WEE1 inhibitors faced. The post Can WEE1 inhibitors finally make r...

Find out about how biotech companies are trying to address the limits the first generation of WEE1 inhibitors faced. The post Can WEE1 inhibitors finally make replication stress druggable? appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.